EMA Recharges Role In Non-EU Drug Approvals
Agency Wants More Firms To Use ‘EU-Medicines4all’ Scheme
Executive Summary
The EMA’s process for assessing medicines for use in non-EU countries is being beefed up after a review showed the mechanism had several flaws that made it unattractive to many companies.
You may also be interested in...
Takeda Test Drives EMA’s Parallel Review Route For EU And Non-EU Markets
A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate.
EMA Offers Simultaneous Review Of Products For EU And Non-EU Markets
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.